Cigna Corporation
Cigna Corporation (CI) Stock Competitors & Peer Comparison
See (CI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CI | $269.39 | +1.32% | 71.4B | 12.05 | $22.17 | +2.27% |
| UNH | $286.36 | +3.36% | 255.9B | 21.29 | $13.24 | +3.13% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| CVS | $76.39 | +0.42% | 96.8B | 55.14 | $1.38 | +3.48% |
| ELV | $294.77 | +2.39% | 64.4B | 11.57 | $25.22 | +2.34% |
| HUM | $171.71 | +4.91% | 19.9B | 16.78 | $9.85 | +2.13% |
| CNC | $34.72 | +0.43% | 17B | -2.55 | -$13.53 | N/A |
| MOH | $150.04 | +0.57% | 7.7B | 16.71 | $8.93 | N/A |
| ALHC | $17.48 | +2.12% | 3.5B | -154.45 | -$0.11 | N/A |
| OSCR | $13.36 | +2.77% | 3.4B | -7.83 | -$1.69 | N/A |
Stock Comparison
CI vs UNH Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, UNH has a market cap of 255.9B. Regarding current trading prices, CI is priced at $269.39, while UNH trades at $286.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas UNH's P/E ratio is 21.29. In terms of profitability, CI's ROE is +0.15%, compared to UNH's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check UNH's competition here
CI vs ANTM Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CI is priced at $269.39, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CI's ROE is +0.15%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ANTM's competition here
CI vs CVS Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, CVS has a market cap of 96.8B. Regarding current trading prices, CI is priced at $269.39, while CVS trades at $76.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas CVS's P/E ratio is 55.14. In terms of profitability, CI's ROE is +0.15%, compared to CVS's ROE of +0.02%. Regarding short-term risk, CI is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CVS's competition here
CI vs ELV Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, ELV has a market cap of 64.4B. Regarding current trading prices, CI is priced at $269.39, while ELV trades at $294.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas ELV's P/E ratio is 11.57. In terms of profitability, CI's ROE is +0.15%, compared to ELV's ROE of +0.13%. Regarding short-term risk, CI is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check ELV's competition here
CI vs HUM Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, HUM has a market cap of 19.9B. Regarding current trading prices, CI is priced at $269.39, while HUM trades at $171.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas HUM's P/E ratio is 16.78. In terms of profitability, CI's ROE is +0.15%, compared to HUM's ROE of +0.07%. Regarding short-term risk, CI is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check HUM's competition here
CI vs CNC Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, CNC has a market cap of 17B. Regarding current trading prices, CI is priced at $269.39, while CNC trades at $34.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas CNC's P/E ratio is -2.55. In terms of profitability, CI's ROE is +0.15%, compared to CNC's ROE of -0.28%. Regarding short-term risk, CI is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CNC's competition here
CI vs MOH Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, MOH has a market cap of 7.7B. Regarding current trading prices, CI is priced at $269.39, while MOH trades at $150.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas MOH's P/E ratio is 16.71. In terms of profitability, CI's ROE is +0.15%, compared to MOH's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check MOH's competition here
CI vs ALHC Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, ALHC has a market cap of 3.5B. Regarding current trading prices, CI is priced at $269.39, while ALHC trades at $17.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas ALHC's P/E ratio is -154.45. In terms of profitability, CI's ROE is +0.15%, compared to ALHC's ROE of -0.00%. Regarding short-term risk, CI is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ALHC's competition here
CI vs OSCR Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, OSCR has a market cap of 3.4B. Regarding current trading prices, CI is priced at $269.39, while OSCR trades at $13.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas OSCR's P/E ratio is -7.83. In terms of profitability, CI's ROE is +0.15%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, CI is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check OSCR's competition here
CI vs CLOV Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, CLOV has a market cap of 1B. Regarding current trading prices, CI is priced at $269.39, while CLOV trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas CLOV's P/E ratio is -11.65. In terms of profitability, CI's ROE is +0.15%, compared to CLOV's ROE of -0.26%. Regarding short-term risk, CI is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CLOV's competition here
CI vs BHG Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CI is priced at $269.39, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas BHG's P/E ratio is -0.12. In terms of profitability, CI's ROE is +0.15%, compared to BHG's ROE of -0.65%. Regarding short-term risk, CI is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BHG's competition here
CI vs CABR Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, CABR has a market cap of 12.5M. Regarding current trading prices, CI is priced at $269.39, while CABR trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas CABR's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to CABR's ROE of N/A. Regarding short-term risk, CI is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CABR's competition here
CI vs BMGL Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, BMGL has a market cap of 11.6M. Regarding current trading prices, CI is priced at $269.39, while BMGL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas BMGL's P/E ratio is -1.24. In terms of profitability, CI's ROE is +0.15%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CI is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BMGL's competition here
CI vs MRAI Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, MRAI has a market cap of 7.7M. Regarding current trading prices, CI is priced at $269.39, while MRAI trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas MRAI's P/E ratio is -0.17. In terms of profitability, CI's ROE is +0.15%, compared to MRAI's ROE of +0.39%. Regarding short-term risk, CI is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check MRAI's competition here
CI vs NIVF Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, NIVF has a market cap of 13.4K. Regarding current trading prices, CI is priced at $269.39, while NIVF trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas NIVF's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to NIVF's ROE of +1.17%. Regarding short-term risk, CI is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check NIVF's competition here
CI vs MGLN Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CI is priced at $269.39, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CI's ROE is +0.15%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CI is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MGLN's competition here
CI vs GTS Comparison March 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 71.4B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CI is priced at $269.39, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.05, whereas GTS's P/E ratio is 10.41. In terms of profitability, CI's ROE is +0.15%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CI is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check GTS's competition here